瑞士巴塞尔大区经济及创新促进局欢迎您

在瑞士最具活力的经济地区培育创新,加速业务发展  >>>>

最瑞士

瑞士是亲商、可靠和高效的代表。巴塞尔地区经济强盛,秉承明确的亲商核心价值,是瑞士这些美德的光辉榜样。  >>>>

生命科学和医疗行业第一

整个生命科学价值链汇聚于一处,且触手可及?这是600家及越来越多的公司对巴塞尔地区情有独钟,将其作为研发、生产和总部的原因。  >>>>

创新行业第一

多项研究结果表明,瑞士是全球最具创新精神的国家。巴塞尔地区丰富的知识、高素质国际人才和强有力的产业支柱使瑞士成为领先的创新枢纽。  >>>>

往来欧洲交通便利度第一

无论是集装箱运输还是空运,巴塞尔地区都拥有交通便利的优势。它与德国和法国接壤,位于欧洲中部的中心地带,是国际贸易青睐的物流枢纽和城市平台。  >>>>

文化和休闲第一

世界级艺术珍宝、文化和体育活动,融入健康自然娱乐景观中的国际化都市氛围,所有这些因素结合在一起,使巴塞尔地区成为全球最适宜居住和工作的地区之一。  >>>>

瑞士巴塞尔大区经济及创新促进局是瑞士西北地区巴塞尔乡村州、巴塞尔城市州和汝拉州为促进创新和经济发展而联合成立的机构。本机构旨在帮助国外企业家和公司在巴塞尔地区成功实践创新,创立公司。

我们拥有15,000名决策者、创新者、专家、影响者和增值者组成的广泛关系网络,让客户能直接获取相关专业知识和技术。

瑞士巴塞尔大区经济及创新促进局主要在以下四个领域内为客户提供定制化服务:

  • 投资巴塞尔地区:提供个性化支持,帮助客户在巴塞尔地区择址。本机构将在整个择址和入驻过程中为公司提供中肯的建议。
  • 为创新着牵线搭桥:帮助生命科学、医疗技术、信息通信技术(ICT)、微技术、纳米及材料和生产技术领域的公司和研究人员在技术、研发和创新事务方面建立联系。
  • 支持创业:为计划在巴塞尔创业的企业家提供全面支持,在其商业计划的运营执行过程中进行协助。此外,以上技术领域中处于扩张模式的初创公司和中小型公司可从策略性交流服务中受益,与行业专家和投资人建立联系。
  • 进驻中国:为瑞士西北部地区寻求扩张到中国的公司提供适当的合作伙伴网络,协助其顺利进驻中国市场,执行扩张项目。

瑞士巴塞尔大区经济及创新促进局还管理着一个综合性信息平台,展示巴塞尔商业地区的优势和专长领域,进一步促进该区域创新公司的融入:

  • “创新报告”:涵盖巴塞尔地区最新创意活动和报告,每月发布一次新闻简报,内容包含采访、背景故事和公司入驻本地的消息。
  • “创新活动”:瑞士巴塞尔大区经济及创新促进局每年组织并合办逾50次专门针对知识转移和创业文化的活动。在“创新活动”中,创新者和企业家分享他们最新的创新理念和经验。

在竞争力和创新能力方面,瑞士已多年位居世界顶级营商目的地前列。多个因素保证了瑞士的领先地位。除了优良的教育和先进的基础设施外,让瑞士等同于亲商、可靠和高效的另一个重要原因就是高效的瑞士政府机构。几十年来,瑞士强有力的法律系统、可靠的规划和稳定的金融体系使得在瑞士经营的公司及其在这里的投资项目都受益匪浅。这种环境也是企业向新市场持续扩张的一个最重要的前提条件。瑞士跨国公司密度全球最高绝非偶然。

巴塞尔地区对瑞士的成功做出了重大贡献。众多国际领先跨国公司不仅发迹于此,这些公司的成功也为该地区的经济增长注入强劲动力。例如,巴塞尔地区的GDP远高于瑞士全国平均水平。大巴塞尔地区人均国内生产总值为瑞士最高。与此同时,巴塞尔在生命科学和其他高科技领域的领先优势推动了瑞士创新能力的发展。例如,瑞士约有占总值五分之一的出口货物在巴塞尔地区制造,考虑到巴塞尔地区人口仅占瑞士人口不到10%,这是十分了不起的成就。

在全球商业、产业和知识竞争力方面,瑞士,特别是巴塞尔地区享有的美誉主要体现在以下四个突出优势上:

  • 明智的税收政策:瑞士采用的联邦制度鼓励州与州之间的财政竞争,使税收保持在合理的范围内。除了联邦层面的统一税率外,各州可自主确定税率,并为公司提供最佳的营商环境。由此,巴塞尔地区的主要受益人是活跃在创新行业、具有高附加值的公司,以及大力投资研发和生产的公司。
  • 自由的劳力市场:由于巴塞尔地区拥有众多活跃于国际的高科技公司,地方政府对于他们对海外高素质专家和高级管理人员的需求采取支持态度。这一欧洲最自由的劳动市场之一使得企业从中受益,同时也给予员工巨大利益。巴塞尔地区的劳动法规和劳力市场使得公司可以在营商环境发生变化并需采取相应措施时能够做出快速反应。
  • 可持续的基础设施:在瑞士,火车晚点5分钟就会令人不快,但这种情况极少发生。这一点常令外国访客露出满意的笑容。众所周知,瑞士的公共基础设施堪称世界上最先进、最可靠的,而巴塞尔地区的优势正在于此。交通四通八达,通过公路、铁路和飞机航线可往返欧洲各地,通过莱茵河的水路可通向全球。
  • 双轨制教育体系:瑞士仅三分之一的年轻人高中毕业后选择继续在瑞士顶尖大学深造。对于很多国家来说,这也许是教育体系的重大失职。但是实际上,这是瑞士在专业技术上成功的一部分原因。瑞士双轨制教育体系旨在确保大多数年轻人完成瑞士联邦认证的学徒期,以尽早参加工作。年轻人可以(也通常会)在瑞士技术学院或应用科学类大学获取专业学位,大多是在职学位。这为瑞士劳力市场稳定提供了经过多年在职培训的入门级雇员,这些人员可以在最具发展潜力的行业进行灵活就业,而雇主和行业实际上也需要这样的人才。此外巴塞尔地区的独特优势在于其拥有众多完善的国际学校,这些学校能够满足外籍人士及其子女的需求,帮助他们轻松融入当地。

作为唯一一个基于直接民主制的政治体系,瑞士在几百年里建立起独特的具有凝聚力的政治和社会文化。其特点是联邦制、自治和一致性,是稳定的政治和社会环境的基石,也是瑞士价值观的体现。巴塞尔地区政府及其民众的开放思想和进取态度,使其成为营商目的地的典范,为企业提供了优良的发展环境,推动企业不断发展壮大。

巴塞尔地区是生命科学领域全球最受欢迎的目的地之一,在欧洲更是无出其右。作为全球市场前三强的罗氏和诺华都是从巴塞尔地区起家,继而将业务拓展至全球。

与之类似的其他跨国公司也在巴塞尔建立了其中心业务分部,其中包括礼来、雅培和拜耳。Actelion、Basilea和Evolva等众多新入驻的公司以及Bachem和Polyphor这样高度专业化的公司使得巴塞尔形成完整的生命科学生态系统。并不令人意外的是,巴塞尔地区还演变成具有发展前景的初创公司钟爱的热点地区。

巴塞尔地区有共计600家生命科学公司,它们对该地区业已颇具活力的营商环境做出重大贡献。这些企业的持续成功主要基于以下三个因素:

  • 生命科学行业是巴塞尔地区经济增长的引擎。这个行业在此生根发芽,且枝繁叶茂:巴塞尔地区生命科学行业的雇员共计2.7万名,每小时生产的产品和服务价值高达3.01亿美元。这使巴塞尔地区成为全球生产力最高的生命科学目的地。巴塞尔地区的生产总值也位居全球之冠:巴塞尔地区的产量全球最高,年产值达130亿美元。与此同时,巴塞尔地区每年获得90亿美元研发投资,是全球这方面数额最高的地区。本地生命科学使经济增长高于瑞士全国平均水平,这使得该行业在巴塞尔地区的声誉无可挑剔。
  • 巴塞尔地区拥有各类人才和专家,而且人数众多:从研发、创办公司到制造、营销和分销,巴塞尔地区拥有一条完整的生命科学价值链,因此您能找到企业在各个发展阶段和各个职能所需的人才和专家。他们人数众多,且经验丰富。加上顶尖的研究机构,如巴塞尔大学生物研究中心(Biozentrum)、苏黎世联邦理工学院(ETHZ)生物系统科学与工程学院和弗雷德里希•米歇尔研究所(FMI),您大致可以了解到巴塞尔地区独特的生命科学资源组合的范围有多广。该地区有触手可及的资源、技术和人才,其深度和密度在全球范围都无可匹敌。这为未来创新提供了独一无二的肥沃土壤。
  • 巴塞尔地区作为生命科学行业的创新标杆已有逾250年的历史:因此巴塞尔地区可谓是涉足生命科学领域历史最悠久的地区。从十九世纪中叶的工业丝带染坊到生物技术革命,巴塞尔的生命科学生态系统不断演进,并在行业的巨大发展中实现了自身突破。这一光辉故事将被续写。与其他曾经实现发展的生命科学中心不同的是,巴塞尔地区在过去几年一直保持稳定和持续的增长。该地区未来几年计划在公共和私人基础设施项目上将投入70亿瑞士法郎,因此下一个高增长期指日可待。

传统优势、强有力的产业支柱、深厚的研发和商业化专长,使得巴塞尔地区成为全球最为完善和成熟的生命科学目的地。您很难再找到另一个像巴塞尔这样适合在生命科学领域高效、可持续和成功地开发科研及商业项目的地区。

高科技是巴塞尔地区经济的推动力,并且是本地经济增长高于平均水平的保障。而且这种局势将持续下去。强有力的产业支柱、吸引全球人才和专家的国际化营商环境,加上瑞士世界一流的教育体系,使巴塞尔地区成为创新的理想环境。在这里,企业,尤其是医疗技术、信息与通信技术、精密机械以及化工业公司都将从该地区的以下特点中受益:                       

  • 巴塞尔地区拥有深厚的高科技产业基础:巴塞尔城市州92%的产业附加值来自高科技公司。类似地,在巴塞尔乡村州和汝拉州,该比例远高于70%,因此高于瑞士60%的平均水平。而瑞士60%的平均水平已使其跻身于世界最具创新精神的国家之列。
  • 巴塞尔地区是研发领域领头羊:瑞士私营部门的研发投资比例高达69%,在全球范围内都属于较高比重。其中40%来自巴塞尔地区,而本地人口仅占瑞士人口的10%。瑞士国内专利最多的十家公司中有五家的总部位于巴塞尔地区,它们是罗氏、诺华、科莱恩、先正达和Endress+Hauser。这也是为什么巴塞尔地区成为瑞士国内聘请研发人员最多的地区。
  • 巴塞尔地区与全球紧密联系,吸引着世界各地的人才:巴塞尔70万居民中约有五分之一来自海外;当前外籍人士达到3.6万人。巴塞尔地区与德法两国接壤,每天有7万名跨境上班族从邻国流入。很难再找到一个地区,像巴塞尔地区这样在如此小的区域内拥有如此具有活力的国际商务氛围,并吸引着全球各地的专业人才汇聚一处。
  • 世界一流的科学和学术教育:除了是强大的产业研发中心外,巴塞尔地区在欧洲学术界举足轻重。巴塞尔大学拥有2,000名教授和1.2万名学生,是欧洲历史最悠久的大学之一,位居全球100所大学之列。从巴塞尔地区乘火车,2小时内即可到达苏黎世联邦理工学院(ETHZ,在巴塞尔设有生命科学学院)和洛桑理工学院(EPFL)。这两所大学都是全球绝对一流的大学。巴塞尔地区(包括其交界国)数百公里范围内共有167家研究机构。此外,瑞士的双轨制教育体系和瑞士西北应用科学大学稳定提供训练有素的高技能专业人才。

研究和调查结果显示,瑞士多年来一直都是全球领先的创新地区之一。强有力的产业支柱、吸引全球人才的全面国际化营商环境,再加上瑞士学术和双轨教育体系,使巴塞尔成为瑞士的创新枢纽。巴塞尔地区的资源密度可谓独一无二:在巴塞尔地区,最高水平的科学表现、行业专长和技术,以及高素质的劳动力都触手可及。


早在罗马帝国时期,巴塞尔莱茵港口就是通向北海航道的最南端港口。1226年,博登湖和北海之间的莱茵河段上建成第一座桥梁(也是此后多年唯一一座),使得巴塞尔演变为重要的贸易枢纽。巴塞尔地区与德国和法国接壤,位于欧洲中部的中心地带,保持了其作为瑞士最重要交通和物流枢纽的领先地位,为本地产业和商业带来诸多利益。
此外,巴塞尔地区特别适合计划在欧洲建立全球总部,以及积极追求全球贸易新机遇的公司。巴塞尔地区具有以下独特优势:

  • 巴塞尔地区是欧洲重要的交通枢纽:从市中心乘出租车或公交仅需15分钟即可到达巴塞尔机场。从该机场可到达欧洲、北美和中东的90多个目的地。集装箱从巴塞尔城的三个莱茵河港口发出,三天内可到达鹿特丹港,而后从那里运往全球各地。火车站每个小时就有一列开往瑞士所有主要城市的火车,如苏黎世(包括苏黎世国际机场)、伯尔尼、洛桑和日内瓦,以及莱茵河畔的各个经济中心(即弗莱堡、卡尔斯鲁厄和斯特拉斯堡)。乘坐高铁几个小时就可轻松便捷地到达欧洲各大都市和首都,如法兰克福、巴黎和米兰。
  • 巴塞尔地区是瑞士领先的物流枢纽:巴塞尔的三个莱茵河港口吞吐量占瑞士外贸总量的12%,其中食品和农产品吞吐量高达84.2万吨。整个巴塞尔地区的外贸额占瑞士总量的三分之一。巴塞尔机场是瑞士领先的货运机场。这使得巴塞尔作为物流枢纽的地位名副其实。巴塞尔物流行业拥有2.3万名从业人员。990家物流公司落户巴塞尔地区,包括市场领导者DHL、Panalpina、Goldrand 和嘉里物流。这些公司可提供成熟的解决方案应对复杂挑战,例如在供应链管理方面,而这正是生命科学和化工业企业常常需要的。
  • 巴塞尔地处欧洲中心位置,是国际贸易公司的理想之选:特种烟草制造商大卫杜夫、零售商Dufry、餐饮公司 Transgourmet 和国际清算银行等各类公司和机构凸显出在巴塞尔交易和提供的货品的多样性。因此瑞士第二大连锁超市Coop和第一大百货公司Manor都选择将总部设在巴塞尔地区。该地区同样是一系列国际贸易展会的重要举办地。每年举办的巴塞尔国际钟表珠宝展(BaselWorld)实现了国际名表和珠宝业的很大一部分销售额。而巴塞尔艺术博览会(Art Basel)则是全球最重要的艺术盛会。越来越多的国际消费品牌已发现巴塞尔作为贸易枢纽的优势,并将欧洲总部设在巴塞尔地区。其中就有美国著名时尚品牌Fossil、自行车制造商Cannondale和时装设计品牌Tally Weijl。

越来越多的跨国公司发现将巴塞尔作为其全球或欧洲总部的吸引力,特别是考虑到巴塞尔出色的连通性和运输系统以及本地在物流和国际贸易上的优势。老字号瑞士公司和初创公司都在利用这里处于欧洲中心所带来的优势。最后,巴塞尔地区毗邻德国和法国,与世界各地交流频繁,本地人口具有世界性,使得整个商业区域生机勃勃,持续增长。

早餐在德国,中餐在法国,晚餐在瑞士:巴塞尔地区地处三国交界处,具备都市化的国际商业氛围,与瑞士其他都市地区相比,人们可以以相对较低的成本享受无与伦比的生活品质。获奖建筑、历史悠久的市中心和从嬉皮士到经典风格的丰富精致的文化生活,都是巴塞尔地区良好城市生活方式的几大支柱。同时,成熟的公共交通系统可快速直达郊区和乡村居住区,以及那里的自然公园和休闲场所。

问一问新来者和新移民:巴塞尔不仅拥有瑞士最大的外籍人士社区,各种国际学校为他们的子女提供教育,而且是定居时间超过5年外籍人士比例最高的地区。原因不止一个:

  • 每个人都能享有巴塞尔的城市生活方式和丰富的文化生活:巴塞尔的根基在罗马和凯尔特人时期就已打下。中世纪末尾至现代初期,该地区首次达到全盛。当然,巴塞尔并未止步于此。现今,巴塞尔繁荣的创意行业、各色当地美味餐馆,以及丰富的文化活动带来了生机勃勃的都市生活方式。在狂欢节时漫步风景如画、历史悠久的市中心,在新巴洛克风格的交响乐厅前停留,或在夏季到明斯特广场观赏户外电影——巴塞尔总是精彩不断。
  • 到了巴塞尔,艺术爱好者就来对了地方:巴塞尔美术馆创立于1671年,被视作历史最悠久的公共社区艺术博物馆。根据伦敦泰晤士报的排名,该馆位列世界5大美术馆之一。另一吸引人的景点是拜尔勒基金会博物馆。该馆由意大利著名建筑师Renzo Piano设计。巴塞尔的另一个艺术重头戏是全球最大的艺术展——巴塞尔艺术博览会(Art Basel)。每年,艺术家、收藏家、画廊和拍卖行以及名流贵宾早早地就在日历里标出博览会举办的日期。他们中有些人会赶来欣赏巴塞尔剧院享誉全球的获奖演出(有歌剧、戏剧和芭蕾舞)。
  • 巴塞尔地区总是充满了运动气息,而且不仅是在体育馆或沙发前的电机上:本地最受欢迎的巴塞尔足球俱乐部(FC Basel)在圣雅各布公园主场迎战欧洲足球顶尖赛事的对手。ATP巡回赛的一流选手参加瑞士室内网球锦标赛,其中包括本地超级球星罗杰·费德勒。在竞技场之外,巴塞尔民众也很热衷于运动。巴塞尔地区自行车使用率为全瑞士最高,包括骑车的上班族和在周边乡间无数自行车道上行进的骑行爱好者。跑步爱好者可在莱茵河两岸的无障碍通道跑步。越野滑雪爱好者可在汝拉州绵延数公里的缓坡上滑行。驱车2小时不到,高山滑雪者和雪板滑雪者就可达到瑞士阿尔卑斯山的原始山坡上。
  • 在瑞士、德国和法国交界处,有各色吸引人的活动等着您:是参加阿尔萨斯的品酒会、巴登-符腾堡南部的美食盛宴,还是在汝拉州山峰上惬意地野餐?在巴塞尔地区,没有一小时车程里满足不了的需求。而且,总会有新发现!想在炎炎夏日跳进沁凉的河水中吗?这时,莱茵河岸线将成为名副其实的地中海里维埃拉——就在巴塞尔市中心。

唾手可及的各色活动、无与伦比的一流公共交通基础设施、安全和稳定的政治局势使得瑞士经常位居生活质量调查排行榜前列。这些都能在巴塞尔地区轻松获得,而艺术文化、生活方式和国际氛围更是锦上添花。因此不足以为奇的是,巴塞尔被瑞士年轻人视作瑞士最具嬉皮士精神和最时尚的地区之一。

我们的服务
Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们

投资巴塞尔地区

您的公司正在扩张吗?您正计划立足欧洲和瑞士,借以打入新市场吗?如是,那么巴塞尔地区正是您的理想之选。您将发现让您长久立于不败之地的要素近在咫尺。

众多跨国公司(主要是生命科学领域)确保了真正国际化的商业环境。巴塞尔地区拥有具有国际思维的人才库,整条价值链和各个职能环节都有高技能人才。巴塞尔地处欧洲中部,毗邻法国和德国,因此可以提供良好的商业环境,以及瑞士闻名于世的生活品质。

您想了解在此地区投资的好处吗?我们很乐意为您展示。我们的专家将在贵公司扩张项目的各个阶段为您提出全面而专业的建议。

  • 评估:税务?就业市场?竞争对手?政府许可?产业环境?我们将根据您独特的项目要求,收集巴塞尔地区及瑞士的所有相关信息和数据。
  • 选址:有任何待解决的问题?我们将寻找合适的专家为您答疑解惑。我们会将您介绍给政府机构、行业和法律专家,并在您置业的过程中提供专业支持。
  • 实地考察:您想亲自了解巴塞尔地区吗?我们将完全根据您的需求精心定制一份高效的实地考察计划和行程。
  • 商业开发:您想让公司业务增长提速吗?我们将帮助您建立与本地合作伙伴和机构之间的联系,加快您进驻巴塞尔地区高度多样化商业和创新生态系统的步伐。                                      

我们的服务将免费提供给那些正考虑择址巴塞尔的公司,这也有助于营造充满活力的商业环境。创新和接受新理念的开放心态是巴塞尔地区的悠久传统。我们期待听取您的商业理念,并协助您一开始就取得成功。

Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss

为创新者牵线搭桥

“为创新者牵线搭桥”服务将创新构想、企业和企业家召集在一起。该服务有两种形式,一种是瑞士巴塞尔大区经济及创新促进局组织的非正式的专家活动,另一种是正式的针对性支持服务,为具体项目提供专家、合作伙伴和融资。我们的专家拥有8000多名创新者组成的强大网络作为后盾。

“为创新者牵线搭桥”服务主要面向以下五大核心主题领域:生命科学、医疗技术、信息与通信技术、生产技术和微技术、纳米技术和材料。每个技术领域都由一名专家专门负责。技术领域经理与行业展开密切合作,制定活动计划,担任项目的联系伙伴,与巴塞尔地区相关研究机构和其他机构培养伙伴关系。

因此,“为创新者牵线搭桥”服务为客户提供了立足于巴塞尔地区、从其多样化创新生态系统受益的理想入口。企业家、创新者和专家每年在逾50场活动上汇聚一堂,定期交流理念和知识,活动形式多种多样:

专题活动:专注于知识转移,为公司、特别是新创公司提供介绍公司和项目的机会,促进巴塞尔地区的创新者进行跨公司和跨学科的经验和知识交流。
研讨会:以拓展新技术应用范围以及发起具体项目和合作企业为目的,通过加强各个公司和学科的专家之间的对话,深度探讨某个主题。
技术与创新圈:运行多年的创新举措,目的是在各个公司和学科所组成的社区中进一步开发主题,以及探索新的市场潜力。

瑞士巴塞尔大区经济及创新促进局的支持创业服务为处于初创阶段的企业提供针对性的活动和服务。

Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们

支持创业

您正计划创业?这太好了,因为巴塞尔地区以创业为生。瑞士巴塞尔大区经济及创新促进局作为巴塞尔地区创新和外来投资的推进机构,为技术和创新领域的企业家提供支持。

我们服务的核心内容是研讨会及工作坊项目:

  • 创始人课程:扶持性服务的核心内容是我们的研讨会及工作坊项目。“创始人课程”基本套餐的目标群体是计划创业的所有意向方。可在此浏览其他课程的概述:课程概述

    更多服务是专门针对在创新和科技领域有具体项目的初创公司和企业家:
     
  • 企业家研讨会及工作坊:在这些活动中,可以就各种商业问题,例如商业计划、融资、产品开发、定价和知识产权,以及营销与沟通进行深入探讨。这一系列活动专门针对有具体创新项目的初创公司和高科技中小型企业。

    除了培训课程和研讨会之外,瑞士巴塞尔大区经济及创新促进局还提供针对具体项目的单独咨询服务。该咨询服务专门针对创新和科技领域增长潜力巨大的公司和项目。
     
  • 联系与咨询:在初期咨询中,我们的专家将评估对支持的需求,并与专业人士、研究机构或潜在合作伙伴建立联系。
  • 新企业评估:在有专人指导下的流程和单独召开的专家会议中,初创公司和创新型中小企业可以请知名的行业专家、企业家和投资人对其商业项目进行评审。更多信息

    瑞士巴塞尔大区经济及创新促进局的服务涵盖创业的初期阶段。目标是在初期构想到实际创业,再到首个实施计划和融资的过程中,提供宝贵信息和切实的建议。这不仅给予企业家更多安全保障,而且可以显著加快他们实施项目的速度。
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们
Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

进驻中国市场

过去几年中,中国作为商业市场的重要性不断提升。中国不仅是低成本消费品生产的海外目的地,也逐渐成为全球主要销售市场。将业务扩张到中国市场将给予公司巨大的发展潜力,尤其是对于中小型高科技公司而言。但想在中国这样复杂的市场占据一席之地,并非易事。

因此瑞士巴塞尔大区经济及创新促进局为巴塞尔地区(巴塞尔城市州、巴塞尔乡村州和汝拉州)的公司提供全面支持,从初期的市场评估、公司考察,直至寻找到商业合作伙伴。除了提供必要的专业知识外,我们的顾问还拥有良好的本地人脉,这些都是多年来与政商界往来所积累起来的。瑞士巴塞尔大区经济及创新促进局还构建有一个颇具规模的公司和专家网络,他们有与中国打交道的丰富经验,了解所有最新发展趋势。

具体而言,客户公司可以从下列服务中受益:

  • 联系与咨询:提供在中国设立经营业务的基础知识,以及由瑞士全球企业(Switzerland Global Enterprise)的专家提供的一对一的个案咨询。
  • 公司和代表团访问:除正式访问计划外,还可与潜在商业伙伴单独建立联系。
  • 活动:以开发新的共同商业潜力为目标,深化中国与巴塞尔地区的交流。

生命科学公司同样能从与上海张江高科技园区和新建的枫林生命科学园区的合作关系中受益,借此打入中国领先的生命科学枢纽。久经考验的中国本地合作伙伴可以提供支持,协助在上海开展业务(包括产品注册、融资、营销等)和与潜在商业合作伙伴及客户建立联系。

Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

我们的渠道: 活动|博客

report BaselArea.swiss

Investing in strengths – Swiss leadership in life sciences

15.05.2017

How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech and Digitization Day, Federal Councillor Johann Schneider-Ammann visited the Basel region to discuss current trends and challenges with a high-ranking delegation from politics, business, research and start-ups.

The importance of life sciences for the Swiss economy is enormous. Last year, the sector was responsible for 45% of total Swiss exports. Similarly, the majority of new relocations are active in the healthcare sector. Switzerland is said to a leading life sciences location in the world with the Basel region as its engine.

It is against this backdrop that Federal Councillor Johann Schneider-Ammann, head of the Federal Department of Economic Affairs, Education and Research, was invited by BaselArea.swiss and digitalswitzerland to visit the Basel region as part of the Biotech and Digitization Day to discuss current trends and challenges in life sciences with a high-ranking delegation from politics, business and research.

The event was held at Actelion Pharmaceuticals and the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft. Federal Councillor Schneider-Ammann emphasised the significance of the region and life sciences industry: “The two Basels have a high density of innovation and successful companies, research institutes and universities. This fills me with pride and confidence. Pharmaceuticals and chemistry are rightly regarded as the drivers of innovation.” But Switzerland cannot rest on its laurels if it is to remain successful in the future; business and politics, science and society must all use the digital transformation as an opportunity, he insisted.

The event was organised by BaselArea.swiss, which promotes innovation and business development in the northwest Switzerland cantons of Basel-Stadt, Basel-Landschaft and Jura, and digitalswitzerland, the joint initiative of business, the public sector and science, whose aim is to establish Switzerland as a leading digital innovation location in the world.

Federal Councillor Schneider-Ammann is currently visiting Switzerland’s leading regions to get an impression of the effects of digitalisation on different business sectors and to talk about promising future concepts.

Supporting biotech start-ups

Life sciences are regarded as a cutting-edge sector with considerable growth potential. But competition among the different locations is becoming more aggressive as other regions in the world are investing heavily to promote their location and attract large companies. A central question of today’s event was: How can Switzerland and the Basel region maintain its leadership role in the face of international competition?

Given its major economic importance in life sciences and when measured against other leading locations worldwide, Switzerland has comparatively few start-ups in this industrial sector. With the launch of BaseLaunch, the new accelerator for healthcare start-ups, BaselArea.swiss and the Kickstart Accelerator from digitalswitzerland have taken a first step to changing this. However, in addition to the lack of seed capital in the early phase of a company’s development, there is also a lack of access to the large capital that an established start-up requires in order to expand. Said Domenico Scala, president of BaselArea.swiss and a member of the steering committee of digitalswitzerland: “We have to invest in our strengths. This is why we need initiatives like Swiss Future Fund, which aims to enable institutional investors to finance innovative start-ups.”

The importance of an innovative start-up scene for Switzerland as a centre of life sciences was also a topic for the roundtable discussion that Federal Councillor Schneider-Ammann held with Severin Schwan, CEO of the Roche Group, Jean-Paul Clozel, CEO of Actelion Pharmaceuticals, Andrea Schenker-Wicki, rector of the University of Basel, and others.

Digitalisation as a driver of innovation

The second topic at the Biotech and Digitization Day was digitalisation in life sciences. According to Thomas Weber, a member of the government of the canton of Basel-Landschaft, this is an important driver of innovation for the entire industry and is crucial to strengthening Switzerland as a centre of research.

In his speech, Federal Councillor Schneider-Ammann focused on three aspects: first, the creation of a new and courageous pioneer culture in which entrepreneurship is encouraged and rewarded for those who dare to try something different. Second, more momentum for start-ups by realising an initiative for a privately financed start-up fund. And third, shaping the role of the state as a facilitator that opens up spaces rather than putting up hurdles or bans.

In the public discussion round, in which representatives from research and industry as well as entrepreneurs participated, it became clear that digitalisation is changing life sciences. Everyone agreed that Switzerland has the best conditions to play a leading role in this transformation process. The basis for this are its powerful and globally actively pharmaceutical companies, its world-renowned universities and an innovation-friendly ecosystem with digitally driven start-ups from the healthcare and life sciences fields. 

digitalswitzerland wants to promote this, too. According to Nicolas Bürer, CEO of digitalswitzerland, healthcare and life sciences are key industries to making Switzerland the leading digital innovation location.

A further contribution can be made by the DayOne, the innovation hub for precision medicine. Launched by BaselArea.swiss in close cooperation with the canton of Basel-Stadt, it brings together on a regular basis a growing community of more than 500 experts and innovators in an effort to share ideas and advance projects.

report ICT

Digital Health – it’s all about Patient Value

24.05.2017

event Life Sciences

A practical guide to financing a Life Sciences start-up

Date: 06.06.2017

Place: Fluxdock AG, Freilagerplatz 3, 4142 Münchenstein

event Accessing China

Swiss-Chinese Life Sciences Forum: Challenges, Responses and Opportunities in the Chinese ...

Date: 15.09.2017

Place: F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel

The Swiss-Chinese Chamber of Commerce, BaselArea.swiss, the University of Applied Sciences Northwestern Switzerland and F. Hoffmann-La Roche AG are organizing the
Swiss-Chinese Life Sciences Forum to promote collaboration between Switzerland and China, in particular in the health sector and life sciences industry and to celebrate the 10th anniversary of the Basel-Shanghai City Partnership.
 
Date: Friday, 15 September 2017, 13:30-17:00h, followed by networking apéro
Venue: F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel
 
Program:

13:00

Door opening

13:30

Welcome address

14:00

Session 1
Challenges Responses and Opportunities in the Chinese Health Sector
Rapid demographic and social changes in China are placing new pressures on the healthcare system as an ageing and increasingly wealthy population seek responses and treatments for ailments associated with a prosperous nation (e.g. Diabetes).
Talks and panel discussion

15:15

Session 2
Digital Health in China
The ultra-rapid expansion of mobile and digital technologies are impacting every facet of life in China today including healthcare. How are these new technologies being applied to solving China’s current and future healthcare problems?
What solutions are being offered by Swiss companies and what are the challenges of delivering these services and solutions in the Chinese environment?
Talks and panel discussion

16:45

Closing remarks

17:00

Apéro

19:00

End

 
The event is free of charge but places are limited.
 
For more information and to register your interest follow this link:
www.swiss-chinese-life-sciences-forum.ch

 

report Life Sciences

Memo Therapeutics platform proves efficacy

24.05.2017

event Production Technologies

Intégration du modèle numérique 3D dans votre approche Industrie du Futur

Date: 14.06.2017

Place: Parc Expo, Salon Industries du futur, 120 rue Lefebvre, Mulhouse

report BaselArea.swiss

The healthcare system must take responsibility

09.05.2017

Kristian Schneider wants to improve the quality of health care and better manage the rising healthcare costs by means of a network that includes doctors, hospitals, insurance companies and the state. Its aim is to provide exactly those services needed for the health of patients. For the canton of Jura, which like all other cantons suffers from the fragmentation of service providers, this could be a unique opportunity to build an integrative care system – and thus become a pioneer, says the director of Hôpital du Jura.

Interview: Fabian Käser, Steffen Klatt

What brought you to the canton of Jura?

Kristian Schneider: I was asked and had 16 hours to decide and submit an application in French. The likelihood of ending up in a high-level managerial position as a nurse is relatively rare. There are only three hospitals in Switzerland that are run by people with a nursing degree.

How did your new colleagues react to a nurse becoming a hospital director?

The reactions were almost all positive. Nurses have a different understanding of the system and speak differently with the people who are supposed to produce health – because they have done it themselves.

How are you received as a German?

I have lived a large part of my life in the greater Basel region. The Jura is not far from there. When I was approached by the canton of Jura in 2012, I was living not far from Belfort, just 20 minutes from the Jura border. This creates an affinity. But I hardly knew the canton. I quickly noticed that the people here are very friendly and open. You can build up a network quickly.

How did you approach the work?

I arrived on 1 January 2013, and the budget was already prepared with a loss of CHF 4.5 million predicted. We then created an action plan to overcome the loss, starting 40 projects to increase resource efficiency and flow efficiency. We were fairly successful in the end.

How did people react?

Although we defined the action plan from above, we made an effort to implement it together with our staff. For example, we had too many operation blocks, and our specialists suggested that we concentrate all operation blocks in Delémont. People knew where we are inefficient; we only have to give them permission to change it. But this also requires a cultural shift.

Where do things stand now?

We broke even in 2013. And we’ve been balancing our accounts since then – while the canton is less and less able to be involved in the hospital. We’ve tidied many things up and have done more in certain areas than other hospitals in the French-speaking part of Switzerland. We’ve since come so far in coding cases that we can now make this service available to other hospitals, such as Neuchâtel. With respect to accounting, our accountants have confirmed that we have the highest quality in the French-speaking part of Switzerland. We were the first hospital to be REKOLE-certified (the system of revising cost accounting and assessments in accordance with the requirements of the Health Insurance Act, ed).

We’ve also better positioned ourselves in the canton. We’re in a unique situation here: as a hospital, we have a “quasi monopoly” in acute care, outpatient care, and also in neuro-rehabilitation and geriatrics. We have 28 per cent of nursing home spots. We therefore cover a good deal of health care in the canton of Jura.

What comes next?

Credit Suisse is forecasting that health insurance premiums are set to double by 2030. In the canton of Jura, this would put 60 per cent of the population below the poverty level. So this raises the question of how we can shape health care in a way that we can still pay for it.

What is driving the costs?

Primarily outpatient care and the age structure. Of course, most of these costs are in the final one or two years, but they begin to rise in the years leading up to this. To prevent this, we need a healthcare system with greater efficiency. Many of today’s costs do not contribute to improving health.

How do you plan to manage the cost drivers?

If I see my role as guiding people through a healthy life, then this also means that people consume only as many healthcare services as they need. So I have to prevent doctors from prescribing services that people don’t really need.

The only way to achieve this is by making all actors take responsibility for the quality and the costs. Doctor have to be paid for keeping their patients healthy.

What could this look like?

We have to build up a network in close cooperation with doctors and change the financing system. Let’s assume that every person has a healthcare budget of CHF 5,000 per year, for instance. Then we would have CHF 360 million for the entire canton of Jura with its 72,000 inhabitants. No more. If something is left over, then it would remain in the network and everyone would have an interest in prescribing only that which brings added value. And there would also be an interest in investing in preventative care.

How would you organise this?

You first have to create a network and regulate it through a framework contract. The most important rule is that everyone only does what is actually necessary. In this network you form a quality committee as a second level, which uses actual cases to examine if the cooperation works. Thirdly, the actors should work together in a physical sense as closely as possible. So if I build a hospital, a healthcare centre should be built right next door to it. And fourthly, the network must invest in preventative care. This can also be because money is left over.

How would you finance the network?

This would be done by the insurance companies. They have no interest in having us exhaust the maximum budget. Insurance companies would therefore sell the model to their policyholders. Insured people who decide in favour of our network would then pay somewhat less than if they had a completely open choice of doctor and hospital.

Isn’t this what Swica is already doing with its healthcare centres?                                                                                              

Swica only does this with primary care, without a hospital. The canton of Jura now has a unique opportunity: it is manageable and has only one hospital

What do you need to build this network?

I would need an experienced partner. And it already exists: Réseau DELTA is a network in the greater Geneva area that is active in primary care. It is very interested in trying something like this with a hospital. We are also talking with Medbase and University Hospital Basel as potential partners. In the end it also needs the canton because the financing model will be changed. But I don’t see a problem there.

Because it will be the same amount just under a new name for the canton?

Precisely. The 55 per cent, which it assumes for hospital accommodation, could be part of the overall budget. It could then show its citizens that healthcare costs no longer have to automatically increase. At least not for those who choose our network model.

When do you begin?

I’m already negotiating now. For the first time since it was founded, the canton is now writing its owner strategy. It has to explain if it has expectations of us as a hospital in regard to the overall costs of the healthcare system. And if yes, if we have the freedom to change the structures. The federal government, which is ultimately responsible for the financing, is open to such models. The canton of Jura could therefore take a step toward a completely different system. It could even establish itself as a region where well-off elderly people spend their last years. This could turn health care into an interesting economic factor in the Jura.

Will you stay in the canton of Jura until you retire?

Enjoying my work matters to me, and I have that here. But I’m unsure if this would also be good for the hospital. Only time will tell. In our past-paced world we need change at such positions, fresh impetus.

About:

Kristian Schneider (45) was born in Frankfurt am Main. He was trained as a nurse in Basel and worked for close to 20 years at University Hospital Basel, the last five years as head of the emergency department. From 2007 to 2009 he completed a diploma programme at the University of Bern in Health Care Management. He has been the director of Hôpital du Jura since 2013. The Jura Cantonal Hospital was formed in 2002 through the merger of the hospitals in Delémont, Porrentruy and Saignelégier and employs 1,655 people.

report ICT

Novartis invests in digital healthcare provider

23.05.2017

event Production Technologies

Webilea Introducing "BaselHack"

Date: 14.06.2017

Place: Halle 7, Gundeldingerfeld, Dornacherstrasse 192, 4053 Basel

report Invest in Basel region

Basel-Landschaft welcomes new companies

21.04.2017

The canton of Basel-Landschaft welcomed a host of new companies over the past few weeks. BaselArea.swiss played in a big role in attracting the companies to establish themselves in Basel.

The companies now represented in Basel-Landschaft are from a variety of different sectors – some work in the sales of medical technology products, others in the manufacture of diagnostic tests. Also newly established in the canton are a music company, a creative agency and a provider of presentation items. BaselArea.swiss consulted these companies and supported them with their establishment.

Medi-CENT Innovation AG, which has offices in Liestal, distributes medical technology products. The company focuses on repairing probes and provides its customers with rental probes in the meantime. Other key areas for Medi-Cent Innovation AG include pain therapy and bone density measurement. Another company now represented in the canton is Predemtec AG. From its location in Binningen, it develops diagnostic tests that can determine the risk factors for dementia.

Musik Hug has opened a new musical world in Allschwil, where it offers a wide range of musical instruments. Its new location also comprises a piano and wind instrument workshop. Newly established in the Dreispitz area is the creative agency MJM.CC AG, which specialises in the production of awards ceremonies, such as the Swiss Film Award and Best of Swiss Web.

Meanwhile, Achilles Präsentationsobjekte GmbH is heading the business of KMC Karl Meyer AG. Thanks to this transition, existing customers can continue to access the consultancy and service portfolio they were accustomed to from KMC Karl Meyer AG. However, they can also access one of the biggest selections of folder and presentation systems in Europe.

report Life Sciences

Basel researchers describe new T cells for cancer immunotherapy

23.05.2017

event Supporting Entrepreneurs

How to Start a Company in Switzerland

Date: 15.06.2017

Place: BaselArea.swiss, Dufourstrasse 11, (4th floor), 4010 Basel

report BaselArea.swiss

“I see a very innovation-friendly climate in Basel”

12.04.2017

It all began with research resources that were a quarter of a century old. Simon Ittig and his colleagues at the Biozentrum of the University of Basel turned these into a research project – and eventually a start-up. T3 Pharmaceuticals develops new therapies to treat solid tumours.

How did T3 Pharma come about?

Simon Ittig: I completed my doctorate at the Biozentum in Professor Guy Cornelis’ group, which dealt primarily with a secretion system of bacteria. Bacteria require these needles to inject proteins into cells and establish their pathogenesis. My doctoral supervisor discovered this mechanism 25 years ago and had researched it ever since. When I completed my doctorate in 2012 and Professor Cornelis retired, I was able to take over many resources such as bacterial strains and study protocols. As a postdoc in another group at the Biozentrum, I dealt with the question of how proteins can be transported rapidly into cells. This brought me back to my collection of bacterial strains, as they are by nature exactly the same. In a short time, I succeeded in showing that such a protein transport does in fact work – and rapidly, efficiently and synchronously. This potential enthralled my research colleagues and me.

What precisely can this technology be used for?

If you have bacteria that transport specific, for example human, proteins into cells, then you can stimulate these cells as you like. It has long been known that bacteria migrate to solid tumours. Accordingly, we focused on the field of solid tumour oncology and could achieve impressive results in a surprisingly short amount of time. We now have bacteria that grow specifically in a tumour over an extended period of time. We can also now program these in such a way that they produce certain active ingredients and pass them into the cells – precisely to where these substances can take effect. Our technology is very stable.

Was it obvious to you that you could go ahead and start a company with this idea?

Yes, this idea came relatively early. We received the first financial support from CTI, the Cancer League and smaller foundations when we were still just academic researchers. It was already clear then that we wanted to become self-employed with our protein transport technology. Founding our own company was even one of the conditions for further research funding from CTI. The Biozentrum supported us in many ways when we were spinning off. As before, the patents belong to the university, but we have an exclusive global license.

How did you finance T3 Pharma?

In the beginning and also subsequently we received substantial amounts of research funding. However, the funds are generally restricted to salaries and materials. Foundations mainly want to finance the actual research work. At some point you reach a limit, which is why we began to actively look for investors for our company.

With great success. What played a decisive role?

First of all, you have to have the right business idea. Second, you need a good amount of mutual trust. The whole set up should be able to accompany the company for several years. If every couple of years you need a few months to secure the next financing round, then this ties up too many resources, creates a lot of uncertainty and distracts from your research activities. For this reason, we looked – and found – investors who had the financial opportunities and necessary understanding, who believe in us and are ready to go the distance with us.

So were you in a privileged position where you could also turn investments down?

Maybe. I’m convinced that you shouldn’t accept every offer if you don’t have to. We carefully examine the conditions connected to the financing and also want to get a sense of the investors’ intentions. It’s also recommended that you keep your options open. If you become content with something too early, it can become very expensive later on.

You have received over 2 million francs from foundations. Is this unusually large for a start-up?

The effort for such financing is of course also very high, especially at the beginning when you can’t yet show proof of your achievements or have yet to receive any research grants. It’s crucial to bring experienced people on board at an early stage. This gives the foundations the necessary certainty when it comes to the project’s feasibility. It’s also important to appreciate smaller amounts. I’m also very grateful that I could learn a lot about the art of writing applications from an experienced and successful scientist, Professor Nigg. With Prof Nigg from the Biozentrum and Prof Christofori from the Department of Biomedicine, we had formed a professional and interdisciplinary consortium from early on. Without these two experienced professors our company wouldn’t exist in its current form.

How high then was the success rate?

I would estimate that half of our requests have been met with a positive result until now.

You’ve come far with this foundation funding, but you’re taking the next steps with the support of private investors. Is this better than turning to venture capital companies?

We of course looked at both alternatives. Private and institutional investors are not mutually exclusive. But we prefer private people because they are generally alone or in small committees and can decide quickly if they want to invest or not. A second point: it’s also important to me personally that we develop an idea together of the next few years and work towards these goals. The interactions, the shared vision and the sense of similar values bring a great amount of pleasure and confidence. It just has to be ‘right’, professional and personal.

How do you go about finding private investors?

Actually, this only goes via a good network and our experienced consultants. In contrast to venture capital firms, private investors tend to remain discretely in the background. It’s therefore important to think early on about the positioning of your own company, the team and its technology. A well-planned communication also helps. Once the ideas are known, it’s easier to get in touch with the right people. If you win someone over in a discussion, there’s a good chance that a private investor will get involved.

What are your next steps?

The financing of T3 Pharm is secured for the time being. We can therefore concentrate on our research and then validate our technology and prepare for preclinical development. As CEO, I’m working outside of the laboratory for the time being while my four colleagues are focussing fully on the research.

What is your long-term vision?

We want to bring our technology for use in patients. This is the major driver in our day-to-day work. How and when we will achieve this goal, I still can’t say today. And also whether or not T3 Pharma will still be an independent company. Who knows what the future holds. We’re therefore open and focused first and foremost on our research.

How do you see the local ecosystem for young entrepreneurs?

We have a good connection to the university and appreciate the open doors. If you trust people and approach them, you receive a lot of support. I see a very innovation-friendly climate in Basel. Of course the large life science cluster creates an incredibly positive environment for start-ups like us. And how BaselArea.swiss promotes innovation also helps in an uncomplicated way when it comes to meeting the right people.

And yet when it comes to start-ups, Basel lags behind other places. What needs to be done?

Nothing works without self-initiative and perseverance. If you have both, you’ll find the best conditions here in Basel and Switzerland. If I had one wish, it would be to more strongly institutionalise the informal exchange at the university. Earlier input from experienced professionals on a start-up idea could help young researchers gather the self-confidence for the next steps and be more successful in presenting their own ideas to a committee. Rejections can be quite discouraging sometimes.

Are there so many ideas that get buried before they’re even given a chance?

Yes, there are, and I find it a real pity. It’s not a matter of course for many people to stand up in front of others and say “I want this, I can do this, and I’ll do it”. Only a few young researchers trust themselves to overcome such a big hurdle and also pursue a project in the face of obstacles. Many talented young scientists remain on the academic track and continue to publish up until the train leaves for a start-up. It would help if they could discuss their ideas informally, without having to shout it from the rooftops. I’m convinced that there would be even more innovative start-ups. Once this hurdle is overcome, you get an unbelievable amount of support even from professors in other fields encouraging you to continue. This is what happened to me.

And was does your doctoral supervisor say about T3?

He’s extremely happy for us. Guy Cornelis also provides us with scientific advice and helps us where he can. The relationship has also since changed and has become very friendly.

About:

Dr Simon Ittig studied biochemistry and biotechnology at the universities of Bern, Vienna and Strasbourg and graduated from the Biozentrum of the University of Basel in microbiology. The start-up T3 Pharmaceuticals grew out of the research project Type 3 Technologies – Bacteria as a versatile tool for protein delivery.

report Life Sciences

Clariant merges with Huntsman

22.05.2017

event Micro, Nano & Materials

Joined Technology Circle "NanoMedicine and NanoPolymers & Structures"

Date: 22.06.2017

Place: ETH Zurich, Department D-BSSE, Misrok-Raum, Mattenstrasse 26, 4058 Basel

report Invest in Basel region

Companies continue to find Switzerland appealing

05.04.2017

Bern – More foreign companies relocated to Switzerland last year than in any previous year. Economic development agencies attracted innovative companies with high value creation.

According to the Conference of Cantonal Economic Affairs Directors (VDK), 265 new foreign companies relocated to Switzerland last year, creating 1,005 new jobs. In 2015, there were 264 relocations and 1,082 additional jobs.

The VDK spoke of “solid results” in the face of a difficult economic environment. Despite the strong franc and uncertainties concerning the general tax and political situation, “Switzerland could obviously hold its ground in the international arena”.

As a summary shows, life sciences was the relocations leader with 60 companies, followed by 52 companies from the ICT sector. 23 relocations each came from the trade and raw materials sector, and the engineering, electrical and metal industries. 18 of the new companies to Switzerland are active in the financial sector, and 12 work in the cleantech and greentech sectors.

This year and in the years to come, Switzerland Global Enterprise – the Economic Development Agency of the federal government and municipalities, and which is led by the national marketing steering committee (SG LM) – will focus increasingly on promoting companies in key industries. In important markets such as Germany, France, Italy, Russia, the US, Japan, India, China, the UK and Brazil, Switzerland can rely on cooperation with the Swiss Business Hubs (SBH) and the Swiss embassies.

report Life Sciences

Polyphor secures additional financing

19.05.2017

event Supporting Entrepreneurs

«Start-up to go» - Rechtliche, steuerliche und buchhalterische Aspekte für Ihr Unternehmen

Date: 22.06.2017

Place: business parc, Christoph Merian-Ring 11, 4153 Reinach